Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

eeding rates were 0.6% and 0.5%, and any bleeding rates were 4.9% and 4.8%, respectively. The RECORD3 trial demonstrated superior efficacy of rivaroxaban versus enoxaparin, with similarly low bleeding rates, in patients undergoing TKR.

Head of Global Development Dr. Kemal Malik, a member of Bayer HealthCare Executive Committee and management board member of Bayer Schering Pharma, commented: "Based on the data we have generated, rivaroxaban shows great promise that it could set a new standard of care in thromboembolic disease as a new benchmark for balancing safety and efficacy in anticoagulation. We hope that the clinical trials will continue to demonstrate the compelling efficacy and safety profile for rivaroxaban, while also demonstrating its utility in both the hospital and home settings without the need for routine monitoring."

The trade name of rivaroxaban is expected to be Xarelto®, pending health authority approval.

Additional Phase III results of the ongoing RECORD program are expected to be available during H2 2007.

Unmet Needs in Venous Thromboembolism (VTE) VTE is a type of thromboembolic disease that affects approximately 6.5 million people worldwide annually. Thromboembolic disease, which is caused by the obstruction of a blood vessel by a blood clot, is a leading cause of global mortality and a concern for many patient populations, including those with atrial fibrillation at risk for stroke; those at risk for acute myocardial infarction (heart attack); those undergoing orthopaedic surgery at risk for developing DVT and PE; and hospitalized, medically ill patients immobilized by cancer, congestive heart failure, acute respiratory disease, or other illnesses.

About Rivaroxaban (Xarelto®) Phase IIb data - presented at ISTH in 2005, and published in the Journal of Thrombosis and Haemostasis in 2005 and 2006, and the additional once-daily ODIXa HIP study published in Circulation in 2006 - indicate that rivaroxaban
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, ... its lead product for the orphan condition acromegaly, today ... financing round. Participants in the financing included new investors ... blue chip public investment fund, as well as existing ... Abingworth and ARCH Venture Partners. Chiasma ...
(Date:2/26/2015)... DALLAS , February 27, 2015 ... Review, H2 2014 market research report to its ... the Corneal Ulcers, therapeutic pipeline. The ... information on the therapeutic development for Corneal Ulcers. ... infections that includes bacterial infections, viral infections & ...
(Date:2/26/2015)... Ill. , Feb. 26, 2015  Today the ... The psychological and physical side effects of ... that opioid painkillers, such as Vicodin and Oxycontin, are ... "More Americans overdose on prescription painkillers than on heroin ... president and CEO of NSC. "Yet, these medications are ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2
... HOERSHOLM, Denmark and SAN DIEGO, California, October 28 ... Wedel, MD, FACP Joins as Vice President and Chief,Medical Officer ... - Stuart Mackey, JD joins as ... Development for Proprietary RNA-targeted,Locked Nucleic Acid (LNA) Drug Platform , ...
... Incorporated (Nasdaq: VPHM ) reported today its financial results for ... million in net product sales including $29 million in net sales ... net income reached $20 million; Improved working capital to $358 ... including cash and cash equivalents of $289 million; and ...
Cached Medicine Technology:Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs 2Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs 3Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs 4ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 2ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 3ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 4ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 5ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 6ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 7ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 8ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 9ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 10ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 11ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 12ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 13ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 14ViroPharma Incorporated Reports Third Quarter 2009 Financial Results 15
(Date:2/28/2015)... 28, 2015 How would you ... , There are all kinds of different leaders, ... awareness of the advantages and applications of different ... launching a new product this spring called The ... the connection between personality type, leadership, and success. ...
(Date:2/28/2015)... 28, 2015 The noted Toronto plastic ... Surgery was recently featured in the January/February 2015 issue ... Dr. David Ellis was featured in an article entitled ... cosmetic enhancements that Kim Cattrall has possibly undergone to ... forehead is smooth without horizontal lines or frown line ...
(Date:2/28/2015)... February 28, 2015 “ Powermod ” was ... which takes a look at the latest and coolest technology ... reporter for NewsWatch and a technology expert, conducted the review ... of charging solutions. , Getting stuck with a low battery ... a problem that people face on a daily basis. Even ...
(Date:2/28/2015)... The World Scout League Commission (WSLC), ... potential EMTs and firefighters, recently announced its decision to ... to raise charitable donations for age-related research. The five-kilometer ... be held on March 29, 2015; registration will start ... 3:30 p.m. , To participate in the race, ...
(Date:2/27/2015)... Sacramento, Calif. (PRWEB) February 27, 2015 ... of liver-disease death, between four and 12 years earlier ... study from UC Davis Health System. , While previous ... ALD than other populations, the new study -- published ... -- is believed to be the first to pinpoint ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2
... University of North Carolina at Chapel Hill have launched a ... help prevent depression and cardiovascular illness in women between the ... may raise eyebrows in some quarters, given that a Women,s ... findings that estrogen therapy resulted in an increased risk of ...
... geneticist Pier Paolo Pandolfi, MD, PhD, is the recipient ... Research) International Award for Cancer Research. This is the ... BIDMC investigator has received this prestigious honor, which was ... renown who has made a major scientific discovery in ...
... the Peninsula College of Medicine and Dentistry are part of ... implement a 4.7m Policy Research Unit dedicated to achieving early ... years by the Department of Health and will be led ... the project include Barts and the London School of Medicine ...
... , WEDNESDAY, Jan. 12 (HealthDay News) -- Even though ... understand many spoken words and use the same brain structures ... The findings challenge the widely held belief that infants ... words, and that this ability begins primitively and evolves into ...
... HealthDay Reporter , TUESDAY, Jan. 11 (HealthDay News) -- Over ... blood pressure drug candesartan stood a higher chance of survival ... fact, 61 percent of those taking candesartan (Atacand) survived, compared ... may be due to differences in the way the drugs ...
... Use of an artery from the arm rather than a ... coronary artery bypass graft (CABG) patients, according to a new ... means that the graft is open and unobstructed -- in ... arm,s radial artery was used in 366 patients and the ...
Cached Medicine News:Health News:UNC researchers investigate estrogen to prevent depression and cardiovascular disease 2Health News:Pier Paolo Pandolfi, M.D., Ph.D., to receive Pezcoller-AACR International Award for Cancer Research 2Health News:Pier Paolo Pandolfi, M.D., Ph.D., to receive Pezcoller-AACR International Award for Cancer Research 3Health News:Funding to improve cancer survival rates 2Health News:Infants Process Words Much Like Adults, Study Finds 2Health News:Not All Heart Failure Drugs Boost Survival Equally 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: